Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm Pilot Study of Patients With Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC) With KEAP1 Mutation Treated With Carbonizumab Combined With Chemotherapy as the First-line Treatment

NCT06341660 is registered in ClinicalTrials.gov with Guangzhou Institute of Respiratory Disease as lead sponsor.

NCT NCT06341660
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06341660 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm Pilot Study of Patients With Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC) With KEAP1 Mutation Treated With Carbonizumab Combined With Chemotherapy as the First-line Treatment
Lead sponsor
Guangzhou Institute of Respiratory Disease
Phase
Phase 2
Overall status
Unknown status
Start date
May 25, 2023
Completion date
July 31, 2025
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer